Every Cure
Adam Kolom is a seasoned entrepreneur and investor with extensive expertise in life sciences and venture capital. As Cofounder and CEO of Related Sciences since April 2019, Adam leads a data science-driven drug discovery firm focused on optimizing preclinical medicine discovery. Adam also owns Startist Innovations, consulting on science-based product development and strategy since 2011. In advisory roles, Adam contributes to Every Cure and previously provided guidance for Parker Media and Emulate, Inc. Notably, Adam co-founded the Parker Institute for Cancer Immunotherapy, where leadership encompassed crafting strategic collaborations and facilitating significant funding initiatives. Prior experience includes managing a $150 million cancer-focused venture fund at the Cancer Research Institute and serving as an investment associate within General Atlantic's healthcare team. Adam holds a Bachelor of Science in Economics from The Wharton School.
This person is not in the org chart
This person is not in any teams
Every Cure
1 followers
Every Cure is a nonprofit organization dedicated to unlocking the full potential of every existing medicine to treat every disease possible. Repurposing existing drugs is the fastest and most efficient way to treat diseases with the greatest return on investment for saving lives. However, systemic barriers impede repurposing, so patients suffer while potential treatments are not fully utilized. Every Cure overcomes these barriers to systematically identify and advance promising repurposing opportunities and save lives. Every Cure is taking a revolutionary and disruptive approach to overcome these systemic barriers by developing a comprehensive, open-source data engine to generate predictive efficacy scores for all 3,000 drugs against all 12,000 diseases and rapidly advance treatments to patients. In partnership with academia, industry, and government, Every Cure is integrating proprietary and public data into a comprehensive dataset, optimizing AI ranking algorithms, validating the most promising drug-disease matches, performing trials, and ensuring patient access to effective therapies.